BOT 1.59% 31.0¢ botanix pharmaceuticals ltd

BOT - Anything but charting, page-10620

  1. 2,232 Posts.
    lightbulb Created with Sketch. 1580
    Here's' what ChatGPT had to say about your post:

    You're right to notice the complexities of drug pricing, especially in the U.S., where pharmaceutical companies charge significantly more than in other countries. Here’s an overview of why that happens:

    -Lack of Price Controls: Unlike many other countries, the U.S. government doesn’t regulate drug prices directly. In countries with socialized healthcare systems (e.g., Australia, Canada, UK), governments negotiate prices with pharmaceutical companies, often capping the amount that can be charged. In the U.S., no such system exists, allowing companies to set prices as high as they believe the market will bear.

    -Market Exclusivity & Patents: Big Pharma can maintain high prices by holding exclusive rights to sell certain medications. Patents and market exclusivity granted by the FDA often allow drug manufacturers to set high prices with little competition for many years.

    -Insurance Complexity: While patients with good insurance may pay little out-of-pocket, the cost doesn’t disappear—it’s borne by insurance companies, which in turn raise premiums for employers and employees. This contributes to higher overall healthcare costs for both private and government-run programs like Medicare and Medicaid.

    -Fragmented Negotiations: In the U.S., insurance companies, hospitals, and other healthcare providers negotiate prices individually with pharmaceutical companies. In other countries, a single entity (often the government) negotiates on behalf of the entire population, leading to stronger bargaining power and lower prices.

    -Research and Development (R&D) Costs: Pharmaceutical companies often argue that high prices in the U.S. are necessary to recoup the costs of drug development, which can be immense. However, this reasoning is controversial because these companies still sell their drugs at lower prices abroad and remain profitable.

    -Advertising and Marketing: The U.S. is one of the only countries where direct-to-consumer advertising of prescription drugs is allowed. The cost of these massive marketing campaigns is factored into the drug pricing.

    -Cross-subsidization: U.S. patients often subsidize the lower prices paid by patients in other countries. Since companies face price controls in other nations, they aim to recoup the bulk of their profits from the less regulated U.S. market.

    Your observation that these costs are passed on to employers, employees, and the government through higher premiums is accurate. It makes healthcare in the U.S. disproportionately expensive compared to other developed nations. Moreover, government programs like Medicare and Medicaid are also burdened by these higher prices, increasing taxpayer costs.

    Selfishly speaking, one thing that is guaranteed out of all of this - we will make some $$ out of it
    Last edited by Grainofsand: 13/09/24
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
31.0¢
Change
-0.005(1.59%)
Mkt cap ! $563.4M
Open High Low Value Volume
31.5¢ 33.0¢ 31.0¢ $1.731M 5.443M

Buyers (Bids)

No. Vol. Price($)
22 606129 31.0¢
 

Sellers (Offers)

Price($) Vol. No.
31.5¢ 92444 5
View Market Depth
Last trade - 16.10pm 19/11/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.